A humanized
single chain Fv antibody fragment specific to the EGP40
antigen was genetically engineered as a
streptavidin fusion (scFvSA) for use in pretargeted
radioimmunotherapy. The scFvSA construct was expressed as a soluble, tetrameric species in the Escherichia coli periplasm at 110-140 mg/liter. The fusion
protein was purified from crude lysates by
iminobiotin affinity chromatography with an overall yield of 50-60%. Characterization of the purified
protein by SDS-PAGE, light scattering, and size exclusion chromatography demonstrated that the fusion
protein was tetrameric with a molecular weight of approximately 172,000. Competitive immunoreactivity assays showed a two-fold greater binding to the
antigen than the comparable whole antibody. The purified
protein had a
biotin disassociation rate identical to recombinant
streptavidin and bound an average of three of four possible biotins per molecule. The radiolabeled fusion
protein showed a faster blood clearance rate in normal mice than the corresponding whole antibody-
streptavidin chemical conjugate.
Tumor-specific targeting of a subsequently administered radionuclidechelate/
biotin molecule was demonstrated in nude mice bearing SW1222 human colon
carcinoma xenografts. A single dose of 800 microCi of
90Y-DOTA-biotin produced cures in mice with established subcutaneous human small cell lung or
colon cancer xenografts.